OpGen (OPGN) Stock Rockets On Clinical Data

OpGen OPGN Stock News

OpGen Inc (NASDAQ: OPGN) is making a run for the top in the market this morning with gains of more than 30% after announcing positive clinical data. The data came from the company’s Acuitas AMR Gene Panel. Here’s the scoop:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

OPGN Rockets On Clinical Data

In an early morning press release, OpGen announced data from its Acuitas AMR Gene Panel and Acuitas Lighthouse Software. The company said that the data will be presented at the ASM Microbe 2019 conference, which will be held from June 20 through June 24, 2019.  

In the release, OPGN said that its presentation will include a comparative analysis of Acuitas Lighthouse and Whole Genome Sequencing for Carbapenemase-producing organisms. 

The comparative analysis is the result of an outbreak investigation conducted by the New York State Department of Health’s Wadsworth Center. The data shows that Acuitas Lighthous comes with a faster turnaround time. 

This is overwhelmingly important as it means that Acuitas Lighthouse can be used as a front-line tool in the clinical setting for both transmission and outbreak detection. 

The reviewers at ASM Microbe 2019 proved to be compelled by the data. After all, the company didn’t just receive general conference acceptance. In fact, the data was selected by reviewers to be featured in a podium presentation. 

The company will also be presenting data from a clinical verification study of Acuitas AMR Gene Panel testing for urine. 

In the study, the company used over 500 remnant urine specimines, collected and tested at the Beth Israel Deaconess Medical Center and Intermountain Healthcare. OPGN said that the data demonstrate that the Acuitas AMR Gene Panel had greater than 90% agreement with quantitative culture for semi-quantitative pathogen detection. 

Moreover, Acuitas Lighthouse phenotype predictions had greater than 90% average total agreement with antibiotic susceptibility testing for E. coli and K. pneumoniae. These are the most common pathogens that cause urinary tract infections. 

Why Investors Are So Excited

The truth is that publicly traded biotechnology companies present data at conferences all the time. So, what is it about today’s announcement that is so exciting for investors? 

First and foremost the data announced by OpGen suggests that its products can be used as a rapid diagnostic to guide early, empiric antibiotic use in patients with UTI from antibiotic resistant bacteria. This alone is great news as the testing has the potential to become a first-line tool in UTI and other diagnostic settings. 

There’s also likely excitement from the conference itself. After all, with both poster and podium presentations, OPGN will be showcasing its accomplishments in front of leaders in the industry, big time investors, and analysts. The company will also hold one on one meetings, likely increasing investor interest in the stock. 

The Potential Here Is Incredible

UTI testing takes place quite often in the United States and around the world. This is especially the case in the hospital setting. As a result, the market is a massive and growing one. 

However, tests can often be incorrect. Perhaps more importantly, tests available today do not provide much data on the bacteria that caused the UTI in the first place. Therefore, choosing the correct treatment option for each patient is more of a guessing game than a science. 

The data offered up by OpGen suggests that they have found a solution to this issue. As such, it wouldn’t be surprising to see hospitals around the world adopting the company’s testing panels and technology in order to provide more precise patient care. 

It’s also worth mentioning that OPGN has a market cap of just under $10 million. With such a small market cap, the company doesn’t need to tackle the entire market to provide a great return of value to investors. In fact, tapping into just a sliver of the global market could produce compelling gains for investors. 

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Final Thoughts

With the positive data and coming presentation, investors have quite a bit to be excited about. This, combined with a very low market cap and a product that has the potential to become a blockbuster in UTI diagnostics makes OPGN a stock that’s hard not to watch!

What Do You Think?

Where do you think OPGN stock is headed moving forward? Join the discussion in the comments below!

Don’t Be Late To The News

Get real time alerts when news breaks by joining the Alpha Stock News mailing list below!

Subscribe Today!

* indicates required

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.